Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Momelotinib versus ruxolitinib in myelofibrosis
NL-OMON44872Phase 3Active, not recruiting
- Sponsor
- Gilead Sciences
- Start
- May 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF) and myelofibrosis (MF) comparing Momelotinib arm with Ruxolitinib arm (2 arms). Primary endpoint: Splenic response rate at Week 24. Started May 2015; status: active, not recruiting.
02
Drugs
mivavotinibruxolitinib
03
Conditions
primary myelofibrosis (PMF)post-polycythemia vera myelofibrosis (PPV-MF)myelofibrosis (MF)
Beyond the preview
Go deeper on NL-OMON44872.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44872.